Classed as a ‘protease inhibitor’, it has been formulated to attack the “spine” of the SARS-CoV-2 virus and stop it replicating in our nose, throats and lungs. At two anonymous Pfizer buildings, one in the U.S. and one in Belgium, a remarkable experiment is under way. Up to 60 volunteers, all clean-living adults aged between 18 and